IntegraGen (7N8) Stock Overview
Provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
7N8 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
IntegraGen SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.19 |
| 52 Week High | €0.49 |
| 52 Week Low | €0.066 |
| Beta | 0.35 |
| 1 Month Change | -11.81% |
| 3 Month Change | 30.48% |
| 1 Year Change | -60.96% |
| 3 Year Change | -85.06% |
| 5 Year Change | n/a |
| Change since IPO | -85.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7N8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.8% | -1.2% | 2.4% |
| 1Y | -61.0% | -5.6% | 3.9% |
Return vs Industry: 7N8 underperformed the German Biotechs industry which returned -5.6% over the past year.
Return vs Market: 7N8 underperformed the German Market which returned 3.9% over the past year.
Price Volatility
| 7N8 volatility | |
|---|---|
| 7N8 Average Weekly Movement | 23.7% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 7N8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7N8's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 37 | Berengere Genin | integragen.com |
IntegraGen SA provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France. The company’s genomic pharma services DNA sequencing for oncology and rare disease research; and NGS testing for cancer research. It also provides MERCURY, an online biological interpretation tool for oncology intended to assist pathologists and oncologists in transforming raw data obtained through high-throughput sequencing into a molecular report for translational and clinical research use; Galileo, a cloud-based app for dynamic exporation of RNA-Seq expression data; and GeCo, a genomic consulting service that offers researchers with access to biostatistics and bioanalytics experts.
IntegraGen SA Fundamentals Summary
| 7N8 fundamental statistics | |
|---|---|
| Market cap | €1.25m |
| Earnings (TTM) | -€2.66m |
| Revenue (TTM) | €5.02m |
Is 7N8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7N8 income statement (TTM) | |
|---|---|
| Revenue | €5.02m |
| Cost of Revenue | €3.96m |
| Gross Profit | €1.06m |
| Other Expenses | €3.73m |
| Earnings | -€2.66m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 21.14% |
| Net Profit Margin | -53.05% |
| Debt/Equity Ratio | -33.5% |
How did 7N8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/18 02:10 |
| End of Day Share Price | 2026/06/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IntegraGen SA is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arnaud Guérin | Portzamparc BNP Paribas |